ARS Pharmaceuticals stockholders elect three Class III directors at 2023 annual meeting

ARS Pharmaceuticals, Inc.

Elected Saqib Islam, Phillip Schneider, Laura Shawver as Class III directors to serve until 2026.
Director vote results: Islam 70.4M for, 3.4M withheld; Schneider 68.7M for, 5.1M withheld; Shawver 69.7M for, 4.1M withheld.
Ratified Ernst & Young as independent auditor for FY2023 with 79.1M votes for, 5,126 against, 4,843 abstentions.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ARS Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-06-27 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-27

Exact text from the filing

Proposal 1: Election of Directors The Company’s stockholders elected the three persons listed below as Class III directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ARS Pharmaceuticals, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-27 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-27

Exact text from the filing

Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

1183 shareholder votes filed in the last 30 days. Browse all shareholder votes →

ARS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-177543

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.